Numinus (TSX-V: NUMI) First Public Company to Test, Sell and Deliver Psychedelic Therapies

Numinus recently completed an over-subscribed private placement and is expected to announce an over-subscribed sub receipt financing shortly, positioning the company well for execution and growth opportunities.

Backstopped by stable cannabis revenue

Sustainable cannabis revenue driven by our testing and processing laboratory provides us a foundation for growth – differentiating us from others in the psychedelics space.
Numinus’ fully built and paid for facility has the capacity to take on THC and CBD product, and is set to be a progressive player in the hemp-derived CBD and cannabis extraction markets upon issuing of its standard processing licence by Health Canada, expected in Q1 2020.

About Numinus

Numinus is a fully integrated operating company at the forefront of the transformative change in treating the growing prevalence of mental health issues and desire for greater wellness.

They will be one of the first publicly traded companies licensed to test, sell and deliver psychedelic therapies

Their unique growth platform includes a testing and processing facility that can leverage the emerging market of psychedelic therapies to treat mental illness, addictions and PTSD, as well as an established and fully integrated treatment and healing centre model that they plan to scale nationally.

Sustainable cannabis revenue through their laboratory and processing facility will help fund growth plans.

Share Structure

Source: Numinus, Psychedelic Finance Feature

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s